<DOC>
	<DOCNO>NCT01177059</DOCNO>
	<brief_summary>The purpose Observational Study long term follow-up Human Immunodeficiency Virus -1 ( HIV-1 ) infect patient receive gene therapy product ( anti-HIV-1 Ribozyme [ OZ1 ] ) part earlier phase 2 trial . Patients see twice yearly 5 year initial infusion study drug elapse yearly rest life . The study monitor record ill effect gene therapy product provide long term safety information .</brief_summary>
	<brief_title>Long Term Follow-Up Study Human Immunodeficiency Virus Type 1 ( HIV-1 ) Positive Patients Who Have Received OZ1 Gene Therapy Part Clinical Trial</brief_title>
	<detailed_description>During early phase 2 base trial ( study # NCT00074997 ) , HIV-1 infect patient receive gene therapy product ( anti-HIV-1 Ribozyme [ OZ1 ] ) . Gene therapy investigational treatment gene insert individual 's cell tissue treat disease . The gene therapy OZ1 think anti-HIV-1 action . This Observational Study provide long term follow-up HIV-1 infected patient receive gene therapy product ( anti-HIV-1 Ribozyme [ OZ1 ] ) part earlier study . Patients see twice yearly 5 year initial infusion study drug elapse yearly rest life . The study monitor record ill effect gene therapy product provide long term safety information . Observational study - investigational drug administer .</detailed_description>
	<criteria>Patients must receive Final Cell Product infusion base study Have sign Informed Consent Form Any patient base study assign placebo arm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>Anti-HIV-1 Ribozyme</keyword>
	<keyword>OZ1</keyword>
	<keyword>HIV-1 Infections</keyword>
</DOC>